20 Results for "

mitotic catastrophe

" in MedChemExpress (MCE) Product Catalog:
Products (20)

20 Results for "mitotic catastrophe" in MCE Product Catalog:

8
8 Publications Verification
Cat. No.: HY-15217
CAS No.: 1333377-65-3
Purity:  96.71%
Target:  

Haspin Kinase

Research Areas:  

Cancer

CHR-6494 is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 inhibits histone H3T3 phosphorylation. CHR-6494 can be used in the research of cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-U00177
CAS No.: 501698-03-9
Target:  

Survivin

Research Areas:  

Cancer

GDP366, a dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1103
CAS No.: 1030384-98-5
Target:  

CXCR

Research Areas:  

Cancer

CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-124757
CAS No.: 932359-76-7
Purity:  99.87%
Target:  

Proteasome Mitosis

Research Areas:  

Cancer

FiVe1 is a vimentin (VIM) inhibitor. FiVe1 binds to the rod domain of VIM, causing metaphase VIM disassembly and hyperphosphorylation at Ser56, ultimately leading to mitotic catastrophe, multinucleation, and loss of stemness. FiVe1 has anticancer activity against soft tissue sarcomas. FiVe1 increases the sensitivity of ovarian cancer to Cisplatin (HY-17394). FiVe1 can be used for researches of mesenchymal cancers (including breast cancer and soft tissue sarcoma) and ovarian cancers .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13737
CAS No.: 882531-87-5
Purity:  98.29%
Target:  

Apoptosis VEGFR FGFR Mitosis

Research Areas:  

Cancer

R1530 is a highly potent, orally active, dual-acting mitosis/angiogenesis inhibitor, with anti-tumor and anti-angiogenic activities. R1530 is a multikinase inhibitor which binds to 31 kinases with Kd values of <500 nM. R1530 inhibits VGFR2 and FGFR1 with IC50 of 10 nM and 28 nM, respectively. R1530 triggers apoptosis (mitotic catastrophe) or senescence .
loading...
    loading...
Cat. No.: HY-172807
CAS No.: 2133007-20-0
Research Areas:  

Cancer

p38α-IN-9 (Compound 2015) is a p38α inhibitor and blocks p38α’s enzymatic activity with an IC50 lower than 20 nM. p38α-IN-9 inhibits MK2 T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis .
loading...
    loading...
Cat. No.: HY-110350
CAS No.: 1458630-17-5
Target:  

Haspin Kinase

Research Areas:  

Cancer

CHR-6494 TFA is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 TFA inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the apoptosis of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be used in the research of cancer .
loading...
    loading...
Cat. No.: HY-P1103A
Target:  

CXCR

Research Areas:  

Cancer

CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
loading...
    loading...
Cat. No.: HY-164501
CAS No.: 1309593-24-5
Target:  

Apoptosis Mps1 Mitosis

Research Areas:  

Cancer

Mps-BAY1 is an MPS1 inhibitor with anticancer activity. Mps-BAY1 inhibits cell proliferation and induces apoptosis by activating mitotic catastrophe in cancer cells, generating global aneuploidy and polyploidy. Mps-BAY1 can be used in the study of colorectal cancer and cervical cancer .
loading...
    loading...
Cat. No.: HY-161521
CAS No.: 2991469-21-5
Research Areas:  

Cancer

PLK1-IN-10 (Compound 4Bb) is an orally active PLK1 PBD (polo-box domain) inhibitor. PLK1-IN-10 blocks the interaction of PLK1 with the cell division regulator protein 1 (PRC1) and decreases the protein expression of the CDK1-Cyclin B1 complex. PLK1-IN-10 reacts with glutathione (GSH) to increase cellular oxidative stress, ultimately leading to cell death .
loading...
    loading...
Cat. No.: HY-179525
CAS No.: 132993-79-4
Research Areas:  

Cancer

DL78 is an effective anti-mitotic agent. DL78 induces mitotic arrest, mitotic catastrophe and apoptosis in cancer cells by disrupting the interaction between Myc and α-tubulin. DL78 exhibits broad anti-cancer activity, especially against cancer cells with chromosomal instability and excessive expression of MYC. DL78 significantly reduces tumor burden in the OV81.2 xenograft model. DL78 can be used for the study of ovarian cancer .
loading...
    loading...
Cat. No.: HY-10919
CAS No.: 138154-39-9
Target:  

Topoisomerase Mitosis

Research Areas:  

Cancer

C-1311 shows to inhibit the catalytic activity of DNA topoisomerase II in vitro and in tumour cells. C-1311 prolongs G2 arrest followed by G2 to M transit and cell death during mitosis in the process of mitotic catastrophe .
loading...
    loading...
Cat. No.: HY-184760
CAS No.: 3022872-60-9
Tubulin polymerization-IN-93 is a β-tubulin polymerization inhibitor. Tubulin polymerization-IN-93 disrupts the microtubule network structure. Tubulin polymerization-IN-93 activates the spindle assembly checkpoint and promotes Mitotic catastrophe. Tubulin polymerization-IN-93 activates the mitochondrial Apoptotic pathway. Tubulin polymerization-IN-93 exhibits anticancer activity against acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-179466
CAS No.: 2551033-16-8
Research Areas:  

Cancer

BKT300 is a potent and selective protein regulator of cytokinesis 1 (PRC1) inhibitor. BKT300 inhibits PRC1 dephosphorylation at T481, disrupts actin and microtubule formation, induces G2/M cell cycle arrest, triggers mitotic catastrophe, and promotes apoptosis, thereby inhibiting proliferation and migration of acute myeloid leukemia (AML) cells while sparing normal cells. BKT300 inhibits tumor growth in mouse xenograft AML models. BKT300 can be used for the research of AML .
loading...
    loading...
Cat. No.: HY-182391
CAS No.: 3084702-28-0
Research Areas:  

Cancer

MKI-3 is a selective microtubule-associated serine/threonine kinase-like (MASTL) inhibitor with an IC50 of 5.72 nM and a Kd of 1.89 nM. MKI-3 disrupts the MASTL-ENSA-Aurora A signaling axis. MKI-3 induces chromosomal instability, mitotic catastrophe and apoptosis (apoptosis) in cancer cells. MKI-3 is applicable to research related to triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-185310A
Research Areas:  

Cancer

MKI-2 hydrochloride is a selective MASTL inhibitor with an IC50 of 37.44 nM. MKI-2 hydrochloride induces mitotic catastrophe resulting from the modulation of the MASTL-PP2A axis in breast cancer cells. MKI-2 hydrochloride reduces phospho-ENSA, total, phospho-c-Myc levels. MKI-2 hydrochloride inhibts cancer cells proliferation, migration and induces DNA damage. MKI-2 hydrochloride inhibits germinal vesicle breakdown in mouse oocytes. MKI-2 hydrochloride can be used for the research of cancer, such as breast cancer .
loading...
    loading...
Cat. No.: HY-185310
CAS No.: 438204-56-9
Research Areas:  

Cancer

MKI-2 is a selective MASTL inhibitor with an IC50 of 37.44 nM. MKI-2 induces mitotic catastrophe resulting from the modulation of the MASTL-PP2A axis in breast cancer cells. MKI-2 reduces phospho-ENSA, total, phospho-c-Myc levels. MKI-2 inhibts cancer cells proliferation, migration and induces DNA damage. MKI-2 inhibits germinal vesicle breakdown in mouse oocytes. MKI-2 can be used for the research of cancer, such as breast cancer .
loading...
    loading...
Cat. No.: HY-W162436
CAS No.: 29115-34-2
MCC1019 is a selective PLK1 PBD inhibitor with an IC50 of 16.4 μmol/L. MCC1019 inactivates the AKT signaling pathway in cancer cells, and induces Apoptosis, Necroptosis and Autophagy. MCC1019 exhibits anticancer activity against lung cancer and prostate cancer .
loading...
    loading...
Cat. No.: HY-181442
CAS No.: 313226-24-3
CK2-TN03 is an ATP-competitive casein kinase 2 (CK2) inhibitor, with an IC50 of 165 nM and a Ki of 20 nM. CK2-TN03 inhibits CK2-mediated survivin activation and reduces CK2-dependent phosphorylation levels of BRD4/MYCN and AKT1. CK2-TN03 exerts anti-neuroblastoma effects by inhibiting survivin, leading to mitotic catastrophe and apoptosis of cancer cells. CK2-TN03 can be used in studies related to neuroblastoma .
loading...
    loading...
Cat. No.: HY-183118
CAS No.: 3064485-16-8
Target:  

CDK Apoptosis

Research Areas:  

Neurological Disease Cancer

CID-078 is an orally active macrocyclic cyclin A and cyclin B inhibitor. CID-078 binds cyclin hydrophobic patches, disrupting interactions of cyclin A-Cdk2 with E2F1 and cyclin B-Cdk1 with Myt1, and selectively targets RxL binding motifs to block complex-substrate interactions. CID-078 induces DNA damage, G2/M cell cycle arrest, apoptosis, mitotic catastrophe, spindle assembly checkpoint activation, and neomorphic cyclin B-CDK2 complex formation, driving synthetic lethality in E2F-driven cancer cells. CID-078 can be used for the research of small cell lung cancer, non-small cell lung cancer, triple negative breast cancer, advanced solid tumors, luminal HR +/HER 2- breast cancer, RB1-altered solid tumors, and neuroblastoma .
loading...
    loading...
  • 1